In the BioHarmony Drug Report Database
Rozerem (ramelteon) is a small molecule pharmaceutical. Ramelteon was first approved as Rozerem on 2005-07-22. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. In addition, it is known to target Rubredoxin. Rozerem’s patent is valid until 2021-11-16 (FDA).
Image (chem structure or protein)